America's Blood Centers
Powered by Community.

NEWSLETTER

A weekly chronicle of events and issues impacting the blood community

2026 Issue #23 **July 27, 2026**

INSIDE:

Narrative Review of Whole Blood Transfusion Published in *JAMA Surgery*....2
REGULATORY NEWS....3
WORD IN WASHINGTON....3
BRIEFLY NOTED....4
MEMBER NEWS....5
PEOPLE....5
Economic Outlook Survey Report Available....7
Register for Part Two of the ABC Executive Fellows Capstone Project Webinar Series.7
Register for the ABC WELC Webinar: Creating Momentum by Empowering Staff Through Wellness, Motivation, and Connections....7
Schedule Released for the 2026 ADRP MasterClass....7
ADRP Trends in Donor Relations Study Results Are Available....8
MEMBER NEWS....8
GLOBAL NEWS....9
COMPANY NEWS....9
CALENDAR....10
POSITIONS....11

Interorganizational Task Force on Domestic Disasters and Acts of Terrorism Urges Blood Donations

The Association for the Advancement of Blood & Biotherapies (AABB) Interorganizational Task Force on Domestic Disasters and Acts of Terrorism, which America's Blood Centers (ABC) is a part of, has published a July 24th statement explaining that blood donations are currently needed to reverse a downward trend. Specifically, the statement noted that, "[f]ollowing weeks of declines in blood donations, the blood supply in the United States is significantly lower than it should be and is trending downward at a concerning pace. Blood centers throughout the country face the risk of not having blood available for every patient when it is needed. The reduced supply is more pronounced in certain regions of the country and among certain blood collectors, which is already impacting the availability of blood for some patients."

The Task Force urged eligible individuals to schedule and keep appointments to donate blood as soon as possible, "[t]o help rebuild the blood supply and ensure blood products are available for all patients." John Hagins, chair of the AABB Interorganizational Task Force on Domestic Disasters and Acts of Terrorism and president and chief executive officer of The Community Blood Center, added in the statement, "[w]e are asking all potential donors — both regular and first-time donors — to make a commitment to donate blood in the coming days and weeks. Donating now, or making an appointment to donate soon, will help ensure that all patients throughout the country have access to the care they need."

The recent communication from the Task Force comes in the wake of July 10th joint statement from ABC, AABB, and the American Red Cross in which the national blood community noted that, "[t]he nation's blood supply is currently strained, and eligible individuals are asked to donate blood or platelets to ensure an adequate supply is available to meet patients' needs. [The blood community] strongly urges eligible individuals throughout the U.S. to schedule a blood or platelet donation appointment as soon as possible. Doing so will help build a stable and adequate blood supply, which saves lives and ensures patient needs are met."

ABC will continue to monitor the situation and provide additional updates as they become available.

(Sources: AABB Interorganizational Task Force on Domestic Disasters and Acts of Terrorism Statement, 7/24/26; Blood Community Joint Statement, 7/10/26)

Narrative Review of Whole Blood Transfusion Published in *JAMA Surgery*

Authors of a paper published in *JAMA Surgery* titled "Whole-Blood Transfusion From Empiricism to Evidence: A Narrative Review" sought to provide an, "integrated overview of whole-blood transfusion in trauma that extends beyond biologic rationale and efficacy alone." [Specifically, the paper aimed] to clarify how whole blood is currently used, where the evidence is strongest, and which critical gaps remain for future investigation."

The review included a section dedicated to "The Future of Whole Blood." The authors hypothesized that the, "future of whole-blood transfusion will be defined not only by new clinical trials, but by data science, system engineering, and policy reform. As the field moves beyond proof of principle, the question shifts from whether whole blood saves lives to how trauma systems can deploy it most effectively, equitably, and sustainably across heterogeneous environments. That shift requires a conceptual reorientation, from product to platform, from hospital intervention to regional capability, and from isolated program to integrated system of care."

Additionally, the paper emphasized that precision deployment is essential. The authors further asserted that, "[b]y integrating trauma registry data, census-level demographics, travel-time networks, and historical injury patterns, it is increasingly feasible to simulate where whole blood would avert the greatest number of preventable deaths and to optimize which vehicles should carry it, at what times of day, and in which regions. Such models have already been developed for stroke, cardiac arrest, and trauma center placement; their extension to whole-blood deployment is both logical and overdue. Another important area of investigation is traumatic brain injury, particularly traumatic intracranial hemorrhage, in which early hemostatic resuscitation with whole blood may be associated with improved outcomes. Emerging observational studies suggest a potential role for whole blood in selected patients with traumatic brain injury, but prospective studies are needed to clarify the patient populations, timing, and transfusion strategies most likely to benefit."

The authors concluded that, "[t]he resurgence of whole blood reflects a rare convergence in trauma care. Physiologic logic, clinical evidence, and ethical clarity have aligned around a single intervention. After decades of fragmentation of blood products, systems, and policy, whole blood has reemerged not as a historical curiosity, but as a promising approach to hemorrhagic resuscitation."

Citation: Torres, C.M., Jenkins, D. and Sakran, J.V. "Whole-Blood Transfusion From Empiricism to Evidence: A Narrative Review." *JAMA Surgery*. 2026.

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2026 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers
Chief Executive Officer: Kate Fry
Editor: Mack Benton
Subscriptions Director: Leslie Maundy
Annual Subscription Rate: $420

Send subscription queries to
memberservices@americasblood.org
America's Blood Centers
1717 K St. NW, Suite 900, Washington, DC 20006
Phone: (202) 393-5725
Send news tips to newsletter@americasblood.org.

REGULATORY NEWS

The U.S. Food and Drug Administration (FDA) has issued a communication titled, "Important Information for Human Cell, Tissue, and Cellular and Tissue-based Product (HCT/P) Establishments Regarding Ebola Disease and HCT/P Donation." The agency stated in the communication that, "[t]ransmission of Ebola disease through use of human cells, tissues, or cellular or tissue-based products (HCT/Ps) has not been described; therefore, the risk of infection transmitted by implantation, transplantation, infusion, or transfer of HCT/Ps remains theoretical. A donor screening test for Ebola disease is not available." The communication noted that, "[r]obust, routine screening measures, for the purposes of making a donor eligibility determination, are already in place for evaluating risk factors and conditions as well as clinical evidence and physical evidence of infection in HCT/P donors. [Based on] information available at this time, establishments may also wish to consider whether, in the 21 days prior to HCT/P recovery, the donor:

- was diagnosed with or suspected of having Ebola disease;
- had close contact with a person confirmed to have or suspected of having Ebola disease;
- resided in or trave[l]ed to a country with widespread transmission of Ebola disease (See Map of Impacted Areas); [or]
- was notified by a federal, state, or local public health authority that he or she may have been exposed to a person with Ebola disease.

FDA will continue to monitor cases of Ebola disease worldwide and available information about potential risks of Ebola disease transmission by HCT/Ps."

(Source: FDA Communication, 7/16/26)

WORD IN WASHINGTON

The Administration for Strategic for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) recently released the agency's "Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) Multiyear Budget (MYB) for fiscal years 2025–2029, outlining the resources needed to strengthen the nation's medical countermeasure preparedness." Key priorities of interest to the blood community outlined in the budget as funding priorities include:

- "the Center for the Biomedical Advanced Research and Development Authority (BARDA) will [s]upport the procurement of dried plasma products as well as the advanced development of next-generation, multipurpose blood products with submission of an application for marketing approval of spray dried plasma anticipated in fiscal year 2027;
- BARDA will [s]upport development of medical countermeasures to address vascular injury, endotheliopathy, gastrointestinal injury, exposure to heavy metals and radioactive isotopes, and next generation blood products as platforms to improve the safety of blood supplies; [and]
- the U.S. Centers for Disease Control and Prevention (CDC) will [c]oordinate with the U.S. Food and Drug Administration (FDA) and other agencies to monitor the safety of the blood supply and any potential vaccines and treatment."

(Source: ASPR Announcement, 7/15/26)

The Cybersecurity & Infrastructure Security Agency (CISA) has published a blog titled "Lessons from CISA's Cyber Incident." The stated purpose of the blog is for the agency to share its experience from a May 2026 internal incident response when an investigative reporter inquired about internal CISA Amazon AWS GovCloud Keys and other information being made available in a public repository. The

(continued on page 4)

WORD IN WASHINGTON (continued from page 3)

reporter received this information from a security researcher whose company continuously scans public code repositories." The agency concluded the blog post by explaining that, "[i]t is not a matter of 'if,' but 'when' a cybersecurity incident will happen to your organization. It is important to the broader cybersecurity community that we address these matters openly to strengthen trust and foster transparency. Such transparency unlocks opportunities for learning that will enhance not only CISA's security posture but that of other organizations as well. CISA shares our incident response experience and key findings in hopes that they will be useful to executives, leaders, and network defenders when assessing and strengthening their environments."

(Source: CISA Blog Post, 7/9/26)

BRIEFLY NOTED

PWW Advisory Group (PWW|AG) and the Prehospital Blood Transfusion Coalition (PBTC) are hosting a webinar titled "The Economics of Prehospital Blood Administration Programs." This virtual event will take place on July 30th at 2 p.m. EDT with the stated learning objectives listed as:

- "[a]nalyze the true costs of prehospital blood administration programs, including readiness expenses, equipment, training, logistics, inventory management, and per-patient program costs;
- [e]valuate the relationship between utilization, patient volume, and program efficiency, and identify factors that influence the financial sustainability of ground and air medical blood programs; [and]
- [d]escribe current reimbursement opportunities and limitations for prehospital blood administration, including ALS2 billing considerations, revenue impacts, and emerging policy issues affecting future program sustainability."

Registration is open. Last month, the organizations shared the results of a national "flash poll" that aimed to, "better understand the economic realities of implementing and sustaining prehospital blood administration programs." An executive summary in the report explained that 55 EMS agencies responded to poll. Reported findings included:

- "the [a]verage annual program expenses range from approximately $36,000 to $77,000 depending on provider type, with total reported annual costs nearing $2 million across respondents;
- the total expense per patient is substantial, averaging nearly $12,000 and exceeding $28,000 in some fire-based systems; and
- reimbursements mechanisms remain limited. Even when optimized, per patient reimbursement increases are modest (approximately 12 percent for ground ambulance) and fall far short of covering the 2,000 percent increased cost per patient. As a result, prehospital blood programs currently operate with a significant funding gap, raising important questions about long-term financial sustainability."

(Source: PWW|AG and PBTC Webinar Announcement, 7/21/26)

The Biomedical Excellence for Safer Transfusion (BEST) Collaborative is reminding interested individuals that it has issued a call for applications for the Scott Murphy Memorial Lecture, which was, "established in 2007 by the BEST Collaborative in recognition of the tremendous contribution of the late Dr. Scott Murphy, a past chair of the BEST Collaborative, [in] the field of transfusion medicine and to the science of platelet storage." The submission deadline is Friday, July 31st, and the decision will be announced by the end of August 2026. "The award[ee] will be invited to attend the entire BEST Meeting [and will be provided] a $500 honorarium and [a stipend] up to $1,000 toward travel expenses [by BEST to the meeting.]" The organization is, "encouraging junior faculty involved in the broadly understood field

(continued on page 5)

BRIEFLY NOTED (continued from page 4)

of transfusion medicine to apply for this unique award. The recipient of the next award will be invited to present during the BEST Meeting (BEST LXXII) in Atlanta, Ga. Oct. 14th-15th. and to network with [the organization's members.]" A listing of previous winners is available. Applications with a letter of interest and C.V. can be submitted online.

The BEST Collaborative has also announced that the call for scientific membership applications is open. The application deadline is Friday, July 31st and decisions will be announced in September 2026. According to the announcement, the organization renews its Board of Directors and scientific membership every four years. "The BEST Collaborative is now, looking for new talent to bring continued scientific vigor and fresh ideas to our team. Members are expected to actively participate in BEST studies, contribute innovative research ideas, and attend our interactive twice-yearly meetings, which alternate between North America in the autumn and Europe in the spring. To support these responsibilities, members will receive a stipend to help offset travel expenses." The four core teams are: "Cellular Therapy (*Current Team Leads: Dave McKenna, MD; David Stroncek, MD*); Clinical Studies/Transfusion Safety (Current Team Leads: Simon Stanworth, MA, PhD; Meghan Delaney, DO); Conventional Components (*Current Team Leads: Jason Acker, MBA, PhD; Denese Marks, PhD*); [and] Donor Studies (*Current Team Leads: Marc Germain, MD, PhD; Ralph Vassallo, MD*)

(Sources: BEST Collaborative Lectureship Announcement, 5/28/26; Scientific Membership Application Announcement, 5/28/26)

MEMBER NEWS

Versiti, Inc. has joined the Blood and Cells Advocacy Roster (BCAR) consortium. "BCAR recognizes the value of established donor recruitment systems, regulated processing environments, logistics capabilities and strong hospital partnerships to advance blood therapies while helping address manufacturing and supply chain challenges in cell and gene therapies," said Versiti Executive Vice President of Clinical Trials Services Brian Bautista in the announcement. "We look forward to applying our experience to support innovation across the advanced therapy and blood therapy ecosystems." According to the blood center announcement, BCAR is an, "industry collaboration between blood and tissue collection networks, related technology providers, biotherapy communities, and other stakeholders that communicates the importance of blood and increasing patient access to life-saving blood and advanced therapies. The nine members of the group are uniquely positioned to pool collective capabilities in order to better understand and address the needs of patients, including an upcoming AI-based data initiative to optimize the blood needs of the underserved sickle cell disease community."

(Source: Versiti Announcement, 7/10/26)

PEOPLE



Amanda Hess, MBA has been named chief progress officer at Our Blood Institute (OBI). According to the blood center announcement, "[she brings] nearly two decades of leadership experience in blood banking, donor recruitment, marketing and community engagement to the nation's seventh-largest independent blood center. [In this role], Ms. Hess will oversee OBI's donor-facing operations, including donor recruitment, donor services, community relations, volunteer services and contact center operations, helping advance OBI's strategic priorities while strengthening donor engagement

(continued on page 6)

PEOPLE (continued from page 5)

and the experience for the thousands of volunteer blood donors who support the organization's lifesaving mission. [She most] recently, she served as vice president of Donor Relations and Marketing for a four-state blood center, where she led donor recruitment and marketing strategies across more than 20 donor center locations.

During her tenure, she helped drive donor growth, improve operational efficiencies, expand community engagement and implement innovative technologies to strengthen the donor experience. Over the past two decades, she has volunteered and facilitated presentations for healthcare organizations, community non-profits, regional business associations and national and international industry organizations, including the ADRP: The Association for Blood Donor Professionals, America's Blood Centers (ABC), Blood Centers of America (BCA), and the Association for the Advancement of Blood & Biotherapies (AABB). She served six years on the ADRP Advisory Board, including during the COVID-19 pandemic, and represented ABC on industry task forces with the U.S. Department of Health and Human Services."

Ms. Hess stated in the announcement, "[b]lood banking has been both my profession and my passion for nearly two decades. What inspires me most is the incredible dedication of the people who give their time, talent and generosity to help patients they've never met. I'm honored to join Our Blood Institute and look forward to working with this exceptional team to continue strengthening our mission and ensuring life-saving blood is available for the communities we serve."


OBI President and Chief Executive Officer (CEO) John Armitage, MD added in the announcement, "Amanda has dedicated her career to strengthening the connection between blood donors and the patients who depend on them. Her experience, collaborative leadership style and commitment to innovation will help OBI continue serving our communities while preparing for the future."

(Source: OBI Announcement, 7/22/26)



Kate Fry MBA, CAE recently celebrated her 10-year anniversary at ABC. She joined the association in 2016 as chief administrative officer before being named CEO in 2018. Throughout her tenure at ABC, Ms. Fry has been recognized as a leader in healthcare association management and advocacy, while leading ABC's strategy development and advocacy work before federal legislators, regulators, and strategic partners.

(Source: ABC Announcement, 7/23/26)



INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

Economic Outlook Survey Report Available

America's Blood Centers (ABC) recently announced that the ABC Economic Outlook Survey Report has been released. The report is complimentary to participants and instructions on accessing it have been distributed to the designated contact. Non-participating ABC members may purchase the report. The ABC Economic Outlook Survey provides a comprehensive look at blood center finances, including 19 of the most frequently used ratios for benchmarking the financial health of an organization as well as median service fees for 30 different blood products and blood center procedures. Please contact us with questions.

Register for Part Two of the ABC Executive Fellows Capstone Project Webinar Series

The first cohort of ABC Executive Fellows are pleased to present their final capstone projects in part two of a special webinar series on Tuesday, August 18th at 2 p.m. EDT. Registration is open as the capstone projects are designed to address opportunities and challenges that impact the broader blood community. Covering a wide range of timely and relevant topics, these presentations offer valuable insights for professionals across all areas of blood center operations. Attendees will have the opportunity to learn from the project teams, engage directly with the authors during Q&A, and bring new ideas back to their organizations. Please contact us for more information.

Register for the ABC WELC Webinar: Creating Momentum by Empowering Staff Through Wellness, Motivation, and Connections

Registration is open for the ABC Women's Executive Leadership Community (WELC) webinar titled "Creating Momentum by Empowering Staff Through Wellness, Motivation, and Connections." This virtual event will take place on August 11th at 1 p.m. EDT. The webinar aims to help attendees discover creative, practical strategies to boost employee engagement, strengthen workplace connections, and motivate teams through wellness, collaboration, and mentorship. With an energetic and interactive approach, the speakers will share fresh ideas to help you build a culture where employees feel supported, inspired, and empowered. ABC members can find additional information including a link to registration here.

Schedule Released for the 2026 ADRP MasterClass

Join us for the 2026 ADRP MasterClass: "The Manager Magnet: Influence and Execution in the Most Complex Leadership Seat!" This virtual event will take place September 16th-17th. View the schedule and register now. In today's competitive market, businesses that prioritize both employee and customer experience gain a significant edge. Join us as we explore:

(continued on page 8)

INSIDE ABC (continued from page 7)

- "the connection between employee engagement and customer satisfaction;
- strategies for creating a positive workplace culture;
- how technology and data improve experiences for employees and customers; and
- real-world examples of companies excelling in both areas."

Whether you're in collections, recruitment, marketing, a customer experience professional, or business executive, this event will equip you with actionable insights to enhance both employee and customer journeys.

ADRP Trends in Donor Relations Study Results Are Available

Participants can now access the results of the *ADRP Trends in Donor Relations Study*. This survey is a strategic tool for blood centers to use in evaluating the performance of collection and recruitment operations and marketing strategies in comparison to your domestic and international colleagues. A key feature of the reporting platform is the ability to view how your operations compare to others using a variety of dynamic filters, including blood center location, collection levels, and employee count. Only centers that participated in the survey will have access to this information. Blood centers that did not participate can purchase the survey report for $599. Please contact us with any questions.

MEMBER NEWS

Versiti, Inc. has joined the Blood and Cells Advocacy Roster (BCAR) consortium. "BCAR recognizes the value of established donor recruitment systems, regulated processing environments, logistics capabilities and strong hospital partnerships to advance blood therapies while helping address manufacturing and supply chain challenges in cell and gene therapies," said executive vice president of Versiti Clinical Trial Services Brian Bautista, MBA in the announcement. "We look forward to applying our experience to support innovation across the advanced therapy and blood therapy ecosystems." The blood center announcement also noted that BCAR is an, "industry collaboration between blood and tissue collection networks, related technology providers, biotherapy communities, and other stakeholders that communicates the importance of blood and increasing patient access to life-saving blood and advanced therapies. The nine members of the group are uniquely positioned to pool collective capabilities in order to better understand and address the needs of patients, including an upcoming AI-based data initiative to optimize the blood needs of the underserved sickle cell disease community."

(Source: Versiti Announcement, 7/10/26)

Sign up for ABC's &ADRP's *Pulse of Leadership*



GLOBAL NEWS

The United Kingdom (UK) has published data from its annual Serious Hazards of Transfusion (SHOT) Report. This is the annual United Kingdom (UK) hemovigilance report that describes transfusion-related adverse events across the UK. Key takeaways from the 2025 available data were:

- "[e]rrors continue to account for majority of the reports. In 2025, 3,358/4,046 (83.0 percent) of all reports (including near miss (NM) and right blood right patient (RBRP)) were due to avoidable errors;
- [t]here were no confirmed or probable transfusion-transmitted infections reported in 2025;
- [t]he risk of death related to transfusion in the UK is 1 in approximately 40,000 components issued, and the risk of serious harm is approximately 1 in 13,500 components issued (includes solvent detergent-treated fresh frozen plasma (SD-FFP) data) based on the reports submitted to SHOT;
- [a] slight reduction has been noted in the total number of transfusion-related deaths (including all imputabilities) reported to SHOT;
- [t]here was one death which was definitely related to transfusion in 2025 — this was following an acute h[e]molytic transfusion reaction (HTR);
- [p]ulmonary complications and transfusion delays were the main causes of reported transfusion related deaths in 2025;
- [n]ear miss events continue to account for a large proportion, 1,370/4,046 (33.9 percent) of the incidents reported to SHOT;
- [i]nadequate staffing, lack of appropriate training, information technology (IT) issues and suboptimal safety culture continue to be identified as contributory factors to numerous incidents reported to SHOT;
- [t]rends in pathological transfusion reactions, like the febrile, allergic, hypotensive, and h[e]molytic reactions are similar to previous years; [and]
- ABO-incompatible (ABOi) transfusions continue to be reported with ineffective pre-transfusion safety checks."

Previous SHOT Reports can be accessed here. "Since 1996 SHOT has been collecting and analy[z]ing anonymi[z]ed information on adverse events and reactions in blood transfusion from all healthcare organi[z]ations that are involved in the transfusion of blood and blood components in the UK. Where risks and problems are identified, SHOT produces recommendations to improve patient safety. The recommendations are put into its annual report, which is then circulated widely and to all of the reporting hospitals. As h[e]movigilance is an ongoing exercise, SHOT can also monitor the effect of the implementation of its recommendations."

(Source: UK 2025 SHOT Report, 7/15/26) ♦

COMPANY NEWS

The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for **Hospira, Inc., a Pfizer Company** for HEXTEND HMW Hydroxyethyl Starch (6%) (Hetastarch). The approval is for a labeling change, in accordance with the "Pregnancy and Lactation Labeling Rule (PLLR). This sNDA approval will not increase production as the FDA's Center for Biologics Evaluation and Research (CBER) added Hetastarch to its "CBER-Regulated Products: Current Shortages" listing as of March 2026. According to the agency, Hetastarch is indicated for, "[t]reatment of hypovolemia when plasma

(continued on page 10)

COMPANY NEWS (continued from page 9)

volume expansion is desired in settings where adequate alternative treatment is unavailable. It is not a substitute for blood or plasma."

(Source: FDA Letter, 7/14/26)

FedEx Corp. recently announced that it has launched **FedEx Life Sciences**. According to a company news release, the new organization will, "support the increasingly complex movement of pharmaceuticals, medical devices, biologics, clinical trials, and other critical healthcare shipments." The company explained that, "[a]s medicine becomes more specialized, global, and time-sensitive, life sciences companies need logistics networks built for precision, visibility, and reliability. From temperature-sensitive therapies and clinical trial materials to medical devices and patient-critical shipments, healthcare supply chains now require specialized support across highly regulated markets. FedEx Life Sciences brings together the strength of the FedEx global network with a dedicated healthcare team and advanced monitoring capabilities to serve pharmaceutical and healthcare professionals working to deliver care to patients around the world."

(Source: FedEx Corp. News Release, 7/9/26) ♦

CALENDAR

Note to subscribers: *Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)*

2026

July 29. **U.S. Food and Drug Administration (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (Virtual).** More information is available here.

July 30. **PWW Advisory Group (PWW|AG) and the Prehospital Blood Transfusion Coalition (PBTC) Webinar: The Price of Saving Lives: The Economics of Prehospital Blood Administration Programs (Virtual).** Registration is open.

August 11. **ABC Women's Executive Leadership Community (WELC) Creating Momentum by Empowering Staff Through Wellness, Motivation, and Connections (Virtual).** More information, including a link to registration, is available to ABC members here.

August 18. **ABC Executive Fellows Capstone Project Webinar Series Session II (Virtual).** More information including a link to registration is available to ABC members here.

August 18. **NHTSA Office of EMS "Establishing a Prehospital Blood Transfusion Program" Webinar (Virtual).** Registration is open. More information is available here.

September 16-17. **ADRP: The Association for Blood Donor Professionals Master Class (Virtual).** Registration is open. More information is available here.

September 22. **NHTSA Office of EMS Working with a Blood Supplier in Your Prehospital Blood Program Webinar (Virtual).** Registration is open. More information is available here.

September 23. **FDA Scientific Public Workshop: Next-Generation Sequencing for Adventitious Agent Detection in Biologics (Virtual).** Registration is open. More information is available here.

(continued on page 11)

CALENDAR (continued from page 10)

September 29. **FDA Blood supply Chain Roundtable Webinar (Virtual).** Registration is open. More information is available here.

October 4-7. **Association for Advancing Tissue and Biologics (AATB) Annual Meeting. San Francisco, Calf.** More information available here.

October 5-7. **ARM Cell & Gene Meeting on the Mesa. Phoenix, Ariz.** More information is available here.

October 14-15. **Biomedical Excellence for Safer Transfusion (BEST) Collaborative Member Meeting. Atlanta, Ga.** More information is available here.

October 17-19. **Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting. Atlanta, Ga.** More information is coming soon.

November 3-4. **Plasma Protein Therapeutics Association (PPTA) Plasma Protein Forum Alexandira, Va.** Registration is open. More information is available here.

October 20. **NHTSA Office of EMS Paying for Your Prehospital Blood Program Webinar (Virtual).** Registration is open. More information is available here.

November 5-6. **2026 ABC Women's Executive Leadership Community *Rise* & Lead Workshop. San Antonio, Texas.** More information is coming soon.

November 17. **NHTSA Office of EMS Prehospital Blood Transfusion Policies, Protocols Guidelines & Training Webinar (Virtual).** Registration is open. More information is available here.

November. 17-20. **American Society for Clinical Pathology (ASCP) and Canadian Association of Pathologists- Association Canadienne des Pathologistes (CAP-ACP) Joint Annual Meeting. Montreal, QC.** Registration is open. More information available here.

December 15. **NHTSA Office of EMS Prehospital Blood Transfusion: Tracking Success & Improvement Webinar (Virtual).** Registration is open. More information is available here.

2027

March 8-11. **2027 ABC Annual Meeting. Atlanta, Ga.** More information is coming soon.

May 11-13. **2027 ADRP: The Association for Blood Donor Professionals Annual Conference Columbus, Ohio.** More information is coming soon.

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: $139 per placement for *ABC Newsletter* subscribers and $279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Business Development Manager. Gulf Coast Blood is seeking a dynamic Business Development Manager to help expand our impact across advanced therapies, research programs, and clinical services. In this role, you will drive business growth by identifying new opportunities, building strategic partnerships, and expanding relationships with hospitals, pharmaceutical companies, biotech firms, and research organizations. You will manage the full business development lifecycle—from prospecting and solution development to deal

(continued on page 12)

POSITIONS (continued from page 11)

closure and ongoing account growth—while supporting innovative programs that help save and sustain lives. **Qualifications:** We are looking for a results-driven professional with experience in business development, sales, account management, or healthcare-related industries. **Advanced therapies or biotechnology background are strongly preferred!** The ideal candidate will have strong relationship-building, communication, and strategic thinking skills, with the ability to navigate complex client environments and identify growth opportunities. **Why join us?** We offer competitive compensation and benefits, career growth opportunities, and the chance to contribute to innovative therapies and services that make a meaningful difference in
patient care throughout our community. If you're passionate about building partnerships and driving innovation, apply today!

Blood Bank Medical Laboratory Specialist (MLS/MLT). Gulf Coast Blood is seeking a dedicated Blood Bank Medical Laboratory Specialist (MLS/MLT) to join our East Texas team and support our lifesaving mission. In this role, you will perform specialized immunohematology and transfusion medicine testing, ensure accurate blood product processing and distribution, maintain regulatory compliance, and contribute to providing safe, high-quality blood products to patients throughout the region. You will work collaboratively with healthcare professionals while upholding AABB, FDA, and internal quality standards. **Qualifications:** We are seeking candidates with a current **MLS or MLT certification (ASCP or equivalent)** and experience in a clinical laboratory setting. Blood banking experience is preferred but not required. Strong attention to detail, critical thinking skills, and a commitment to quality patient outcomes are essential. **Why join us?** We offer competitive compensation and benefits, opportunities for professional growth, and the chance to make a meaningful impact in the communities we serve. If you're passionate about laboratory science and helping save lives, we encourage you to apply today.

Medical Apheresis LVN. Gulf Coast Blood is seeking a dedicated **Medical Apheresis LVN** to support our mission of providing safe, high-quality blood components to hospitals and patients across the Texas Gulf Coast region. As an Apheresis Nurse, you will provide donor and patient care through apheresis and leukapheresis procedures. This role includes phlebotomy, peripheral IV and central line care, medication administration and monitoring the donors receiving mobilizing agents. The nurse will monitor patients throughout the procedure. The nurse ensures documentation meets regulatory standards and maintains compliance with AABB, FDA, FACT and internal policies. **Qualifications:** We're looking for someone who has graduated from an accredited vocational or nursing program with a current LVN license. Request at least four (4) years of recent direct patient care experience, preferably in acute care with strong peripheral IV skills. Apheresis or dialysis experience is strongly preferred. Must hold BLS or ACLS certification and have reliable transportation for travel to donor and group sites. **Why join us?** We offer a **competitive compensation and benefits package**, free parking at the Texas Medical Center, opportunities for career growth, and a supportive workplace focused on excellence and mission. Apply Today!

HR Director. At Stanford Blood Center (SBC), how we treat our people is just as important as the life-saving work we do. We're looking for an **HR Director** who shares that belief — and brings the experience, courage, and heart to help us live it every day. This is a strategic partnership. You'll work closely with our VP and senior leadership to advance SBC's people agenda, navigate a mission-driven organization within a large health system, and be a trusted resource for managers and staff alike. You bring the same resourcefulness to HR that SBC brings to its mission: finding a way forward. What we're looking for: A leader with presence and warmth in equal measure — someone people at every level feel comfortable approaching. A strategic thinker who brings an HR lens to organizational conversations, not just day-to-day problem solving. Someone who has navigated tough situations and comes out with relationships and trust intact. Solid experience with California employment law and labor/union relations. Background in high-volume, people-intensive environments: healthcare, retail, or similar. Ten to 15 years of progressive HR experience with a track record of follow-through. Requirements: Bachelor's degree in Human Resources, Business Administration, or relevant field. Minimum 10 years of progressive HR experience with increasing responsibility. We're a close-knit team doing work that saves lives. If you're energized by meaningful work and want an HR role where you can make a genuine difference, we'd love to hear from you. Click here to apply. Questions? Contact Miriam Garrido, Talent Acquisition Consultant Miriam1@stanford.edu.

Regional Director (Tallahassee, FL). OneBlood is seeking an experienced Regional Director to oversee donor blood collection operations and lead regional teams in support of its lifesaving mission in the Panhandle. This leadership role is responsible for driving operational excellence, ensuring compliance with regulatory and accreditation standards, and achieving donor recruitment and collection goals across the region. Candidates should possess strong leadership, analytical, communication, and team management skills, along with the ability to build collaborative relationships and improve operational performance. A bachelor's degree

(continued on page 13)

POSITIONS (continued from page 12)

and significant management experience in healthcare, blood banking, or a related field are preferred. Travel within the region may be required. This position is based in Tallahassee, Florida, and offers the opportunity to join a mission-based organization dedicated to maintaining a safe and reliable blood supply for local communities. Competitive compensation and a comprehensive benefits package offered. Apply at **OneBlood Careers**.

Executive Director (Brussels, Belgium). Reporting directly to the EBA (European Blood Alliance) President and working closely with the Executive Board and central office team, the Executive Director will oversee EBA operations, functions, and activities, and lead the EBA through its next phase of development and influence. This is a role for an individual who is comfortable operating at the intersection of healthcare, science, policy, regulation, competent authorities, and international relations. Key responsibilities include: Lead and develop EBA as a modern, effective, and influential European membership organization. Work with the President, Executive Board, and central office team to shape strategic priorities and organizational direction. Manage the day-to-day operations, governance, and financial stewardship of EBA. The individual will have: Experience building organizational capability, capacity, and effectiveness. An ability to operate independently whilst maintaining strong engagement with Boards and senior stakeholders. The successful candidate shall have and be able to demonstrate: Significant leadership experience in a complex organization or international environment. Knowledge of European Policy, Regulation, and Competent Authorities. Experience engaging with European institutions and international organizations. Experience: At least 3 years' experience in a leadership role in a complex organization or international environment. At least 3 years' experience in a role directly involving European Policy, Regulation, and Competent Authorities. Knowledge of additional European languages. Please click here to view the full job description. To apply, please contact Peter O'Leary, EBA Executive Director (departing). The deadline to apply is **August 7th**.

Director of Mobile Operations (Austin, TX). Oversee the management of all mobile and support operations, which includes but is not limited to medical history, donor eligibility, automated component collection and whole blood collection processes, as well as staff scheduling, quality control, and education and training in conjunction with the Director, Fixed Site Operations. Establish and maintain quality practices while continually seeking to improve and expand upon performance and knowledge for self and staff. A minimum of five (5) years management experience, including strategic planning, or a minimum of three (3) years blood center senior management experience is required; blood center or relevant industry-related experience may be substituted for some management experience. Blood center experience in donor collection operations management strongly preferred, particularly experience with FDA/ AABB and/ or Industry audits. College degree and/or RN license preferred. Either of these may substitute up to two (2) years management experience. Must be at least 21 years old, possess a valid driver's license, and be able to provide a copy of an acceptable driving record and proof of liability insurance. Ability to maintain a flexible schedule, including travel, evenings, weekends, and on-call responsibilities. Click here to apply.

Immunohematology Reference Laboratory Manager. LifeSouth Community Blood Centers is looking for a leader with a passion for making a difference to join our Immunohematology Reference Laboratory team in Atlanta, GA. **Legal authorization to work in the United States is required. We do not provide visa sponsorship for this position.** Shift differential applies to eligible evening and overnight hours. This position is responsible for leading staff engaged in performing laboratory testing and related activities in our AABB-accredited reference laboratory. The IRL Manager is expected to provide day-to-day onsite supervision of testing personnel and reporting of test results under the direction of the Laboratory Director. This position is also responsible for performing laboratory procedures and reporting of test results, as well as ensuring compliance with established laboratory policy and with applicable governmental regulatory requirements from agencies such as CLIA, FDA, AABB, HIPAA, and state licensing regulations. Join our team and help us continue our mission to make sure blood is available when it's needed most. Visit our careers page to learn more about this position, and apply here!

Medical Laboratory Scientist. LifeSouth Community Blood Centers is looking for experienced Medical Laboratory Scientists, with a passion for making a difference. Current openings: Gainesville, Florida (Multiple shifts available; rotating weekends and holidays), Jacksonville, FL (Overnight), and Atlanta, Georgia (Morning shift; rotating weekends and holidays). **Legal authorization to work in the United States is required. We do not provide visa sponsorship for these positions.** Shift differential applies to eligible evening and overnight hours; sign-on and/or relocation bonuses may also be offered to qualified candidates. Our Medical Laboratory Scientists work in a full-service, accredited immunohematology laboratory following established policies and procedures to resolve complex immunohematology and compatibility problems to provide the safest donor blood for patients in our community. Join us in our mission to make sure blood is

(continued on page 14)

POSITIONS (continued from page 13)

available when it's needed most. Visit our careers page to learn more about this position and apply today!

Laboratory Supervisor (Evenings). LifeSouth Community Blood Centers is looking for an experienced Laboratory Supervisor with a passion for making a difference to lead our evening shift Immunohematology Reference Laboratory team, in **Gainesville, FL**. Shift differential applies to eligible evening and overnight hours; sign-on and relocation bonuses may also be offered to qualified candidates. In this role, you'll oversee daily operations, ensure adherence to established policies and procedures, and support staff in resolving complex testing and compatibility challenges. You'll play a critical part in identifying and addressing issues that may impact test performance or result reporting, while mentoring and guiding team members to uphold the highest standards of quality and safety. Your leadership will help ensure the delivery of the safest donor blood for patients in our community. We are committed to excellence in customer service and patient care. Join us in our mission to make sure blood is available when it's needed most. Visit our careers page to learn more about this position and apply today!

Purchasing Manager. LifeSouth Community Blood Centers is seeking a highly skilled leader with proven management experience and a passion for making a difference. The **Purchasing Manager** at our headquarters location in **Gainesville, FL** is responsible for vendor selection, negotiation, establishment and maintenance of all purchased materials, supplies, equipment, and services used by the company. The Purchasing Manager is organized and decisive and can motivate the team to reach daily and long-range goals. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and apply here!